Asset Details
Do you wish to reserve the book?
Painful diabetic neuropathy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Painful diabetic neuropathy
Do you wish to request the book?
Painful diabetic neuropathy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Painful diabetic neuropathy
2014
Overview
Diabetes is a worldwide epidemic, and associated neuropathy is its most costly and disabling complication. Given the rising prevalence of painful diabetic neuropathy, it is increasingly important that we understand the best ways to diagnose and treat this condition. Diagnostic tests in this field are evolving rapidly. These include the use of skin biopsies to measure small unmyelinated fibers, as well as even newer techniques that can measure both small unmyelinated fibers and large myelinated fibers in the same biopsy. The main treatments for painful diabetic neuropathy remain management of the underlying diabetes and drugs for the relief of pain. However, emerging evidence points to major differences between type 1 and type 2 diabetes, including the ability of glycemic control to prevent neuropathy. Enhanced glucose control is much more effective at preventing neuropathy in patients with type 1 diabetes than in those with type 2 disease. This dichotomy emphasizes the need to study the pathophysiologic differences between the two types of diabetes, because different treatments may be needed for each condition. The impact of the metabolic syndrome on neuropathy in patients with type 2 diabetes may account for the difference between the two types of diabetes and requires further study. Finally, neuropathic pain is under-recognized and undertreated despite an ever evolving list of effective drugs. Evidence exists to support several drugs, but the optimal sequence and combination of these drugs are still to be determined.
Publisher
British Medical Journal Publishing Group,BMJ Publishing Group LTD
Subject
/ Analgesics - therapeutic use
/ Analgesics, Opioid - therapeutic use
/ Biopsy
/ Cyclohexanecarboxylic Acids - therapeutic use
/ Diabetes
/ Diabetes Mellitus, Type 1 - complications
/ Diabetes Mellitus, Type 1 - drug therapy
/ Diabetes Mellitus, Type 2 - complications
/ Diabetes Mellitus, Type 2 - drug therapy
/ Diabetic Neuropathies - diagnosis
/ Diabetic Neuropathies - drug therapy
/ Diabetic Neuropathies - etiology
/ Fibers
/ gamma-Aminobutyric Acid - analogs & derivatives
/ gamma-Aminobutyric Acid - therapeutic use
/ Humans
/ Hypoglycemic Agents - therapeutic use
/ Kinases
/ Pain
/ Skin
/ Studies
